Bahrain has become the second country in the world and the first in the Middle East to approve the use of CASGEVY (exagamglogene autotemcel) for treating sickle cell disease and transfusion-dependent beta-thalassemia. The treatment, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, underwent successful clinical trials in several countries before receiving approval in Bahrain. This milestone marks a significant advancement in medical possibilities and reinforces Bahrain’s commitment to pioneering healthcare solutions.
CASGEVY utilizes the revolutionary gene-editing technique called CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) to treat a wide range of genetic disorders. By editing patients’ own stem cells, scientists can produce fully functioning hemoglobin, offering hope for previously untreatable conditions like sickle cell anemia. Bahrain’s authorization of CASGEVY demonstrates its dedication to improving the health and well-being of its people and positioning itself at the forefront of medical advancements in the region.
The approval by the National Health Regulatory Authority (NHRA) of Bahrain follows a thorough analysis and review. Currently, sickle-cell patients in Bahrain have limited treatment options, making the authorization of CASGEVY a significant turning point. Dr. Ahmed Alansari, CEO of the NHRA, praised Bahrain’s visionary leadership and commitment to innovation, stating that the approval showcases the country’s determination to improve the lives of its citizens through the highest quality of healthcare and wellbeing.
